p35/CDK5 Regulates Bladder Cancer Proliferation and Migration and Promotes Higher Tumor Grade and Poor Survival Rate in Patients With Bladder Cancer

Oner M., Lin E., Chiu K., Chen M., Prince G. M. S. H., Lai C., ...Daha Fazla

ANTICANCER RESEARCH, cilt.44, sa.2, ss.543-553, 2024 (SCI-Expanded, Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 44 Sayı: 2
  • Basım Tarihi: 2024
  • Doi Numarası: 10.21873/anticanres.16842
  • Dergi Adı: ANTICANCER RESEARCH
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, Biotechnology Research Abstracts, CAB Abstracts, EMBASE, Gender Studies Database, Veterinary Science Database
  • Sayfa Sayıları: ss.543-553
  • Karadeniz Teknik Üniversitesi Adresli: Hayır

Özet

Background/Aim: Bladder cancer remains a
significant global health concern, necessitating a deeper
understanding of the molecular mechanisms underlying its
progression. Cyclin-Dependent Kinase 5 (CDK5) has recently
emerged as a potential player in bladder cancer pathogenesis.
This study investigated the involvement of CDK5 in bladder
cancer, emphasizing its potential as a therapeutic target.
Materials and Methods: The expression levels of CDK5 and
p35 (CDK5 regulatory protein) and their roles in the tumor
grade and malignancy of patient samples were evaluated using
western blot analysis and immunohistochemistry. In addition,
tumor cancer genome atlas (TCGA) was utilized to evaluate
survival rate in patients with bladder cancer. We further
confirmed the role of CDK5 with in vitro experiments using
western blot analysis, immunocytochemistry, cell culture-based
proliferation and migration assays. Results: Higher CDK5 and
p35 were associated with a higher tumor grade and poor
survival rate in patients with bladder cancer. To confirm the role
of CDK5 in vitro, we over-expressed CDK5 in bladder cancer
cells. The results showed that the over-expression of CDK5
enhanced bladder cancer cell proliferation and migration. In
addition, CDK5 inhibition by a pan-CDK inhibitor, Roscovitine
(RV), significantly reduced proliferation of bladder cancer cells.
Indeed, the migration and adhesion of bladder cancer cells
were inhibited by RV treatment. Conclusion: CDK5 might play
important roles in bladder cancer progression and be a
potential diagnostic and therapeutic target in the near future.